Objective: To evaluate the efficacy of the addition to milk, 5 min and 10 h before its consumption, of a lactase obtained from Kluyveromyces lactis in lactose malabsorbers with intolerance. Design: Double-blind, placebo-controlled, crossover study. Setting: University Hospital. Subjects: In total, 11 male and 19 female (aged from 18 to 65 y, mean age 43.3 y) lactose malabsorbers with intolerance participated. Interventions: Each patient underwent three H 2 breath tests, in a random order. We used 400 ml of cow's semiskimmed milk as substrate and a b-galactosidase obtained from K. lactis. The test A was carried out adding to the milk the enzyme (3000 UI), 10 h before its consumption; the test B was performed adding the b-galactosidase (6000 UI) 5 min before milk ingestion and the test C was made using placebo. We evaluated the maximum breath H 2 concentration, the cumulative H 2 excretion and a clinical score based on intolerance symptoms (bloating, abdominal pain, flatulence and diarrhoea). Results: Our study showed a significant reduction of the mean maximum H 2 concentration after both test A (12.0777.8 p.p.m.) and test B (13.9777.99 p.p.m.) compared with test C (51.46716.12 p.p.m.) (ANOVA F ¼ 54.33, Po0.001). Similarly, there was a significant reduction of the mean cumulative H 2 excretion after both test A (142871156 p.p.m.) and test B (17617966 p.p.m.) compared with test C (579572707 p.p.m.) (ANOVA F ¼ 31.46, Po0.001). We also observed a significant reduction of the mean clinical score after both test A (0.3670.55) and test B (0.9670.85) compared with test C (3.770.79) (ANOVA F ¼ 106.81, Po0.001). Moreover, with regard to the mean clinical score, there was a significant reduction after test A with respect to test B (Bonferroni's P ¼ 0.03). Conclusions: Our study shows that in lactose malabsorbers with intolerance, the lactase obtained from K. lactis can represent a valid therapeutic strategy, with objective and subjective efficacy and without side effects.
Introduction
Lactose malabsorption is characterised by deficiency of lactase, an intestinal enzyme that hydrolyses lactose to its components galactose and glucose (Gilat et al, 1972) . It is a very common condition, reaching 70% in southern Italy (Gudmand-Hoyer, 1994) . High concentrations of lactase are physiologically present in neonates; nevertheless, postweaning, a genetically programmed and irreversible reduction of its activity occurs in the majority of the world's population (Wang et al, 1998) .
The presence in the colonic lumen of malabsorbed lactose does not necessarily result in gastrointestinal symptoms.
When this condition is related to uncomfortable clinical manifestations as bloating, abdominal pain and diarrhoea, 'lactose intolerance' occurs (Shaw & Davies, 1999) . Worldwide, up to 50% of malabsorbers exhibits symptoms (Rosado et al, 1984) . Nowadays, the usual behaviour for this condition consists of the avoidance of milk and dairy products from the diet. However, this restriction leads to a reduction of intake of substances such as calcium, phosphorus and vitamins, and may associate with decreased bone mineral density (Solomons et al, 1985a, b; Di Stefano et al, 2002) . To overcome these limits, in the last years, several approaches have been studied: drugs that increase contact time between enzyme and substrate, either delaying orocoecal transit (ie loperamide) (Szilagyi et al, 1996 (Szilagyi et al, , 2000 or delaying gastric emptying (ie propantheline) (Peuhkuri et al, 1999) ; continuous lactose consumption to induce colonic adaptation (Briet et al, 1997) ; substitutes for milk (Swagerty et al, 2002) ; yogurt and probiotics for their bacterial bgalactosidase activity (Onwulata et al, 1989; Saltzman et al, 1999) ; addition of exogenous lactase to the milk before its consumption (Solomons et al, 1985a, b; Barillas & Solomons, 1987; Corazza et al, 1992; Lin et al, 1993) . In particular, replacement therapy resulted in an efficacious strategy; nevertheless, only few double-blind and/or placebo-controlled trials have been performed.
We have evaluated, in a double-blind, placebo-controlled, crossover study, the efficacy of the addition to the milk, 10 h and 5 min before its consumption, of lactase obtained from Kluyveromyces lactis in lactose malabsorbers with intolerance.
Patients and methods
We enrolled 30 patients (11 male, 19 female; aged from 18 to 65 y, mean age 43.3 y), referred to our Day Hospital of Internal Medicine and Gastroenterology because of symptoms compatible with lactose intolerance, and who were lactose H 2 breath test positive. Each patient underwent, in a random order, three H 2 breath tests. An interval of at least 72 h was allowed among successive tests, to avoid the effect of colonic acidification. We used 400 ml of cow's semiskimmed milk as substrate (containing about 20 g of lactose), and a b-galactosidase obtained from K. lactis (Silact, Sofar SpA, Trezzano Rosa, MI, Italy).
The test A was performed adding the enzyme to the milk, with mild mixing, 10 h before its consumption (preincubated): the temperature of milk during incubation was 41C; the test B was carried out adding the b-galactosidase 5 min before milk ingestion (mealtime) and the test C was made using placebo.
Concentration of b-galactosidase was 5000 U/ml; 0.3 ml corresponds to 1 drop of used enzyme. While in test A, we used 3000 U (2 drops) of lactase, and in test B we added 6000 U (4 drops). These quantities were chosen considering the units able to hydrolyse, in the two different preparations, at least 70% of present lactose, as suggested by the manufacturer. One neutral lactase unit is the quantity of enzyme that incubated at 251C and pH 7.5 with o-nitrophenyl-b-D-galactopyranoside produces 1 mmol of o-nitrophenyl per minute. Test C was performed using aspartame, a sweetening substance not able to digest milk, because galactose and glucose are more sweet than intact lactose.
An investigator prepared milk with either enzyme or placebo in numbered containers, identical in shape and colour. Another blinded investigator administered treated milk to the patients. Enrolled subjects did not have any information about the content of milk.
The evening before the test, all subjects consumed a meal of only rice, meat and olive oil to avoid the probable influence, on the basal H 2 values, of a prolonged gas production due to the presence of nonabsorbable or slowly fermentable material in the colonic lumen. After an overnight fast, and a mouthwash with chlorhexidine to eliminate the possible early hydrogen peak due to the fermentation of the ingested sugar by oropharyngeal bacteria, patients received the milk with either enzyme or placebo. Smoking and physical exercise were forbidden 1 h before and throughout the test. Sampling of alveolar air was performed by means of a commercial device, which allows the first 500 ml of dead space air to be separated and discarded, while the remaining 700 ml of end-alveolar air is collected in a gas-tight bag (Gasampler Quintron, Milwaukee, WI, USA). Subjects were instructed to avoid deep inspiration and not to hyperventilate before exhalation.
For the analysis of H 2 concentration in air samples, we used a dedicated gas chromatograph (Model 12i, Quintron Instrument, Milwaukee, WI, USA). Breath samples were taken at fasting and every 30 min for 4 h after milk ingestion. Hydrogen concentrations were expressed in parts per million (p.p.m.). An increase in H 2 concentration of at least 20 p.p.m. above the basal value was considered indicative of lactose malabsorption. We evaluated the maximum H 2 concentration and the cumulative H 2 excretion, the latter obtained using the formula for the sum of areas of consecutive trapezoids, in accordance with Kotler et al (1982) .
For 8 h following milk ingestion, all subjects kept a diary where they recorded the eventual occurrence of intolerance symptoms whose severity was indicated by a score. Considered symptoms were bloating (absent ¼ 0; mild ¼ 1; moderate ¼ 2; severe ¼ 3), abdominal pain (absent ¼ 0; mild ¼ 1; moderate ¼ 2; severe ¼ 3), flatulence (absent ¼ 0; mild ¼ 1; moderate ¼ 2; severe ¼ 3) and diarrhoea (absent ¼ 0; present ¼ 3). For every patient, a cumulative index was calculated by the sum of the partial score of each symptom. Obtained data were collected by a blinded investigator and were analysed by a blinded statistician.
Statistical analysis
Statistical analysis was performed by means of one-way analysis of variance (ANOVA). Post hoc comparison was (Figure 1) ; the reduction percentage was 77 and 73%, respectively.
Similarly, there was a significant reduction of the mean cumulative H 2 excretion when the lactase was added to milk both 10 h (142871156 p.p.m.) and 5 min (17617966 p.p.m.) before its consumption with respect to placebo (579572707 p.p.m.) (ANOVA F ¼ 31.46, Po0.001) ( Figure 2) ; the reduction percentage was 76 and 70%, respectively.
The curves of breath hydrogen displaying half-hour intervals with mean (7s.d.) obtained in test A, test B and test C are shown in Figure 3 .
We also observed a significant reduction of mean clinical score after the addition of lactase to milk either 10 h (0.3670.55) or 5 min (0.9670.85) before its consumption compared with placebo (3.770.79) (ANOVA F ¼ 106.81, Po0.001) (Figure 4) ; the reduction percentage was 90 and 75%, respectively.
Finally, no differences in the mean maximum H 2 concentration and in the mean cumulative H 2 excretion were found with preincubated milk or adding enzyme at mealtime (Figures 1 and 2) ; instead, about the mean clinical score, there was a significant reduction when lactase was added 10 h rather than 5 min before milk consumption (Bonferroni's P ¼ 0.03 group A vs group B) (Figure 4 ).
Discussion
The use of exogenous b-galactosidase in lactose malabsorbers was shown to be efficacious and without any side effects. Initially, this approach was judged as not practical because of the necessity to add the enzyme some hours before milk consumption (Rask Pedersen et al, 1982; Onwulata et al, 1989; Lin et al, 1993) . Other studies, carried out to resolve this matter, have demonstrated the efficacy of the lactase also when added at mealtime (Solomons et al, 1985a, b; Barillas & Solomons, 1987; Corazza et al, 1992) . Nevertheless, until now just a few double-blind and/or placebo-controlled trials have been performed. For this reason, although replacement therapy with lactase does not represent a novel strategy, we designed a double-blind, placebo-controlled, crossover study using two different prehydrolysed prepara- We found a significant reduction of the H 2 production and symptoms score when the milk was prehydrolysed by bgalactosidase with respect to placebo. In particular, both preparations were efficacious in reducing the mean maximum H 2 concentration and the mean cumulative H 2 excretion. These results do not fully resemble the previous studies and this can be explained by some observations: firstly, by the different enzyme origin. Comparative studies had already shown the major efficacy of the lactase derived from K. lactis with respect to the enzyme obtained from Aspergillus niger (Rosado et al, 1984; Solomons et al, 1985a, b) . In this way, we could explain the results obtained by Corazza et al. In fact, they added a lactase derived from A. niger to the milk at mealtime and obtained a lower reduction both of maximum H 2 concentration (about 38%) and cumulative H 2 excretion (about 43%) than us (Corazza et al, 1992) . The dose of enzyme is another factor that should be considered. Lami et al (1988) , in a double-blind study, found a percentage reduction of the H 2 maximal peak of about 39% if 2000 UI of lactase from K. lactis was added at mealtime, and of about 58% when 1000 UI of the same enzyme was added 12 h before milk consumption. We can speculate that a linear relationship exists between the dose of lactose and the units of b-galactosidase required to improve digestion. So, our better results could be explained by the three-fold quantity of lactase that we used.
Also regarding clinical aspects, our study showed very satisfactory results. In particular, we found a significantly symptoms score reduction of both milk-lactase preparations compared with placebo; moreover, we have found a slight significant improvement when lactase was added 10 h rather than 5 min before milk consumption. It is not easy to explain the significance of this difference about subjective parameter. In our opinion, despite this little difference, we can advise the use of the enzyme also at mealtime, because of its greater practicality.
The clinical aspect should be considered more relevant than the H 2 excretion; in fact, in malabsorber patients with intolerance, since there are no known adverse effects of lactose maldigestion other than acute gastrointestinal symptoms, the major end point is to resolve the clinical picture. Just for this reason, the treatment is reserved exclusively for intolerant subjects (Suarez et al, 1995) . Moreover, there is emerging evidence that malabsorbed lactose could act as a prebiotic and so could be beneficial against some lower intestinal diseases (Szilagyi, 2002) .
Low-lactose/lactose-free products should be strongly suggested in malabsorber patients with intolerance to avoid the common behaviour of limiting intake of milk and dairy products. Certainly, the already on-sale lactose-free milk is more practical than addition of exogenous b-galactosidase. On the other hand, the possibility to use the lactase makes feasible milk consumption also when lactose-free milk is not available and when intolerant subjects are away from home (ie restaurant, cafeterias, home of friends, etc.). Moreover, other commercially available preparations of lactase (in capsules or tablets) could be very useful and easy to use, overall for solid dairy products. Nevertheless, previous studies have shown that these preparations were less effective than prehydrolysed milk, probably because of gastric inactivation of the enzyme (Onwulata et al, 1989) , and more expensive (Suarez et al, 1995) .
Finally, even though our diary was not specifically addressed to evaluate the palatability, none of our patients reported about taste alteration of the milk treated with exogenous lactase, as previously described (Onwulata et al, 1989) .
Conclusions
In lactose malabsorbers with intolerance, the use of the prehydrolysed milk with the b-galactosidase obtained from K. lactis results in an effective and rational therapeutic approach, accepted by patients, without side effects, with objective satisfactory results (reduction of H 2 excretion) and with reduction of the gastrointestinal symptoms. 
